Discovery rx vct 64 pet ct scanner

Participants underwent structural MRI and a dual-phase Florbetapir-PET scanning at the Cyceron Center (Caen, France) on a Philips Achieva 3T scanner (Eindhoven, The Netherlands) and a Discovery RX VCT 64 PET-CT scanner (General Electric Healthcare, Milwaukee, WI), respectively. Acquisition details have been previously reported^{6 (link),35 (link)} and are available in eMethods, links.lww.com/WNL/C821.

All participants were scanned on the same scanners at the Cyceron center (Caen, France).
A T1‐weighted image and a fluid‐attenuated inversion recovery (FLAIR) were acquired on a Philips Achieva 3T scanner in all participants (n = 134).
Fluorodeoxyglucose positron emission tomography (FDG‐PET) and florbetapir‐PET were obtained on two separate days on a Discovery RX VCT 64 PET‐CT scanner (General Electric Healthcare). FDG‐PET scans were acquired on a subset of 92 individuals (59 women), while florbetapir‐PET was obtained in all but one participant (n = 133). A dual‐phase florbetapir‐PET scan was performed, including a first 10‐minute scan starting at the time of injection (early florbetapir‐PET), used to measure brain perfusion, and a second 10‐minute scan starting 50 minutes after the injection (late florbetapir‐PET), used to quantify amyloid burden. Early Florbetapir‐PET scan was missing in one additional participant due to a scanner issue, such that early Florbetapir‐PET was available for 132 participants. Final sample size per imaging modality is provided in the Flow Chart (eFigure 1, Supplementary Material). Details on acquisition parameters and procedures for magnetic resonance imaging (MRI) and PET images can be found elsewhere²⁴ and in the Supplementary Material (eMethods).